Back to today’s briefing

Story perspectives

Vigil Neuroscience's VG-3927 Shows Promise in Alzheimer's Trial

1/24/2025

46 9

Summary

Vigil Neuroscience Advances

Vigil Neuroscience is making waves with its promising phase 1 trial results for VG-3927, a groundbreaking Alzheimer’s treatment. The trial revealed a significant reduction of soluble TREM2 in cerebrospinal fluid, showcasing effective target engagement. With plans for a phase 2 trial set for Q3 2025, hope is on the horizon for those battling this devastating disease.

Summary

Dementia Prevention Insights

A groundbreaking review of over 130 million patient records uncovers a potential silver lining in dementia prevention. Antimicrobials, anti-inflammatory drugs, and vaccines may lower the risk, while antipsychotics and some diabetes medications could heighten it. This research opens doors for repurposing existing drugs, urging further exploration to unravel these critical connections.

1 of 2

Vigil Neuroscience Advances

Vigil Neuroscience is making waves with its promising phase 1 trial results for VG-3927, a groundbreaking Alzheimer’s treatment. The trial revealed a significant reduction of soluble TREM2 in cerebrospinal fluid, showcasing effective target engagement. With plans for a phase 2 trial set for Q3 2025, hope is on the horizon for those battling this devastating disease.

1 / 2